This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bristol Myers' (BMY) sBLA for Orencia Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Bristol Myers' (BMY) sBLA for Orencia under a priority review to prevent moderate to severe acute graft versus host disease. A verdict is pending on Dec 23, 2021.
Paratek's (PRTK) Nuzyra Gets FDA's Orphan Drug Tag for NTM
by Zacks Equity Research
The FDA bestows an Orphan Drug designation to Paratek's (PRTK) marketed drug Nuzyra for the treatment of infections caused by Nontuberculous Mycobacteria.
Kodiak Sciences (KOD) Q2 Earnings Lag, Eye Candidate in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss for the second quarter of 2021. Pipeline development remains in focus for the company.
Down 23.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corvus (CRVS)
by Zacks Equity Research
Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Bionano (BNGO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Bionano Genomics (BNGO) is likely to provide updates on earnings and revenues when it reports second-quarter 2021 results.
Anavex (AVXL) to Report Q3 Earning: What's in the Cards?
by Zacks Equity Research
On Anavex's (AVXL) earnings call for the fiscal third quarter, investor focus will mainly be on the company's progress with its lead investigational candidate for Alzheimer's disease.
Will Teladoc (TDOC) Q2 Earnings Show Weak Telehealth Demand?
by Zacks Equity Research
Teladoc's (TDOC) Q2 results are likely to reflect a rise in revenues but overall tepid demand as patients started visiting doctors' clinics for in-person checkups.
Down 15.8% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Biotech Stock Roundup: ALXN to Raise Guidance, BMY to Buy MYOK & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with regulatory, acquisition and other pipeline updates.
Corvus Pharmaceuticals (CRVS) Catches Eye: Stock Jumps 8.4%
by Zacks Equity Research
Corvus Pharmaceuticals (CRVS) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Biotech Stock Roundup: REGN Initiates Coronavirus Study, NVAX Surges & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Corvus Starts Immunotherapy Study on Coronavirus, Stock Rises
by Zacks Equity Research
Shares of Corvus (CRVS) rise as it commences a phase I study to investigate a novel immunotherapy approach for patients with COVID-19.
What Makes Corvus (CRVS) a New Buy Stock
by Zacks Equity Research
Corvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ziopharm Oncology (ZIOP) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Ziopharm Oncology (ZIOP) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
New Strong Buy Stocks for December 21st
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Sarepta Stock More Than Doubles This Year So Far: Here's Why
by Zacks Equity Research
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is also making good progress. The company is also developing gene therapies.
Corvus Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Corvus Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
Quest Diagnostics (DGX) Looks Good: Stock Moves 6% Higher
by Zacks Equity Research
Quest Diagnostics Incorporated (DGX) shares rose to 6% in the last trading session.
Top Ranked Momentum Stocks to Buy for April 21st
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, April 21st:
Top Ranked Momentum Stocks to Buy for April 19th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, April 19th:
Top Ranked Momentum Stocks to Buy for April 17th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, April 17th:
Top Ranked Momentum Stocks to Buy for April 12th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, April 12th:
Top Ranked Momentum Stocks to Buy for April 6th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, April 6th:
3 Reasons Why Corvus Pharmaceuticals (CRVS) is a Great Momentum Stock
by Zacks Equity Research
Corvus Pharmaceuticals (CRVS) is a solid momentum stock that has a favorable Zacks Rank and is seeing solid earnings estimate revisions.
Top Ranked Momentum Stocks to Buy for April 4th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, April 4th: